SecBot SecBot
8-K ·Filed Aug 3, 2026

GKOS

GLAUKOS Corp
NEUTRAL
Impact 3/10
Horizonmonths Processed3mo ago SEC0001192448-26-000002
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor upcoming quarterly results for execution against $690M revenue guidance and adoption trends of iDose TR and Epioxa. No immediate trading catalyst from this filing.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

GKOS drug pipeline →

iDose TREX

● Neutral Named in this 8-K
Impact
Phase
Phase 2b/3
Time to market
Unknown; Phase 2b/3 trials typically take 2-4 years to complete, so potential approval would likely be 2028-2030 at earliest, assuming positive data.
Next catalyst
None dated

What to watchMonitor for interim or topline data readouts from the Phase 2b/3 program, which could serve as a catalyst. The next meaningful update may come at a major ophthalmology conference. Meanwhile, iDose TR commercial adoption trends and quarterly earnings are the primary near-term drivers for GKOS stock.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$170.87
T+0 close · Aug 3, 2026 · via day close
Latest settled
+7.68%
T+60 · $184.00
Vs SPY
+5.90%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 3 $170.87entry
  2. T+1 · 4mo ago −0.20%α −2.00% · $170.53
  3. T+5 · 3mo ago +6.17%α +4.15% · $181.42
  4. T+20 · 3mo ago +5.09%α +3.85% · $179.56
  5. T+60 · 21d ago +7.68%α +5.90% · $184.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Glaukos filed an 8-K furnishing an August 2026 investor presentation. The presentation reiterates previously disclosed 2026 revenue guidance of $690M, highlights 85% non-GAAP gross margin, $289M cash with no debt, and a strong pipeline including iDose TR and Epioxa. No new material financial information or guidance changes are introduced.

Key Facts

  • 2026 revenue guidance midpoint of $690M, unchanged from 2Q 2026 earnings call on 7/29/2026
  • 2Q 2026 non-GAAP gross margin of 85%
  • Cash and equivalents of $289M with no debt as of 6/30/2026
  • $900M invested in R&D since 2018
  • 30% topline growth in 2025 and 20% 10-year revenue CAGR
  • iDose TR approved for re-administration (Jan 2026) and Epioxa commercially available (March 2026)
  • Multiple late-stage pipeline programs: iDose TRIO (Phase 3b), iDose TREX (Phase 2b/3), Retina XR (Phase 2a)

Financial Impact

No new financial impact; presentation repeats prior guidance and operating metrics

revenuegross margincashR&D spending

Risk Factors

  • Commercial adoption of iDose TR and Epioxa may underperform expectations
  • Pipeline clinical trial delays or regulatory setbacks
  • Competitive pressure in interventional glaucoma and keratoconus markets

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001192448-26-000002
Document: gkos-ex99_1.htm0001192448-26-000002
Document: 0001192448-26-000002-index-headers.html0001192448-26-000002
Document: 0001192448-26-000002-index.html0001192448-26-000002
Document: 0001192448-26-000002.txt0001192448-26-000002

Track record

16 reports on GKOS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $242.67 Now $244.88 +0.91% settles Nov 23
  2. Nov 12, 20264d ago 144 Neutral 3/10 Entry $245.72 Now $244.88 −0.34% settles Nov 20
  3. Nov 6, 202610d ago 8-K Neutral 3/10 Entry $224.41 to $245.72 Now $244.88 +9.12% ▲ +9.50% +6.90% vs SPY
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $224.41 to $245.72 Now $244.88 +9.12% ▲ +9.50% +6.90% vs SPY
  5. Nov 4, 202612d ago 144 Neutral 2/10 Entry $246.70 to $247.16 Now $244.88 −0.74% ▲ +0.19% +1.10% vs SPY
  6. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $246.70 to $247.16 Now $244.88 −0.74% ▲ +0.19% +1.10% vs SPY
  7. Oct 30, 202617d ago 144 Neutral 3/10 Entry $237.60 to $224.41 Now $244.88 +3.06% ▼ −5.55% −2.85% vs SPY
  8. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $242.48 to $219.98 Now $244.88 +0.99% ▼ −9.28% −4.55% vs SPY
  9. Aug 13, 202613w ago Insider Cluster Neutral 3/10 Entry $184.53 to $184.89 Now $244.88 +32.70% ▲ +0.20% +1.56% vs SPY
  10. Aug 11, 202613w ago Insider Cluster Neutral 2/10 Entry $186.63 to $189.55 Now $244.88 +31.21% ▲ +1.56% +2.01% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 3, 2026